Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

OriGene Awarded NCI Contract

Published: Monday, February 03, 2014
Last Updated: Monday, February 03, 2014
Bookmark and Share
The contract will see OriGene to develop high affinity anti-peptide antibodies for SISCAPA assays.

Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA) , an approach developed by Dr. Leigh Anderson , is a novel technology that  can achieve high sensitivity quantitation of proteins in clinical samples using  affinity - capture  SRM Mass spectrometry. One of the most desirable aspects of SISCAPA technology is that it h as the potential for simultaneous quantification of multiple  proteins from a given sample making it is highly desirable in  many applications to minimize sample requirements, handling, and assay costs per analyte . However, the capabilities of the SISCAPA technique are currently limited due to the scarcity of high  affinity antibodies to the specific peptides that are generated by the fragmentation  of the target  protein before analysis.  

Producing high quality antibodies for SISCAPA assays fits well with OriGene's long term goal  of developing perfect assays for every human protein. The development of these  antibodies is being performed  in  partnership with the Institute for Systems Biology (ISB) and in  coordination with NCI's Clinical Proteomic Technologies for Cancer (CPTC) group. OriGene has previously collaborated with Dr. Robert Moritz , Director of Proteomics Research at ISB , for the generation  of mass spec peptide profiles from over 5000  full length  human proteins for inclusion in the complete human SRMAtlas . For the generation of high - affinity SISCAPA antibodies under this contract, OriGene will utilize a novel immunization  strategy to develop high antibody titers in rabbits and will utilize the  proteomics capabilities of the Moritz lab to identify , isolate and characterize the highest affinity antibodies suitable for SISCAP A approaches . 

Dr. James Lazar, Vice President of Assay Development said, “OriGene is pleased to have been selected by NCI to receive this contract and to work with Dr. Moritz , a leader in this field. We believe that OriGene’s unique expertise in antibody development  will enable the true potential of SISCAP A technology and contribute to the development of important clinical assays”. 

Dr. Moritz commented : “ This is a fantastic opportunity  where we continue our collaboration  with OriGene  and combin e our collective knowledge and expertise in antibody generation and  protein chemistry to provide  ‘digitized ’ antibodies for the NCI CPTC program at the NIH and  support the effort of shared resources .”  


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

OriGene Awarded Contract to Develop Monoclonal Antibodies for SISCAPA
OriGene Technologies have announced that they have been awarded a Phase II SBIR contract from the National Cancer Institute (NCI) to develop high-affinity, anti-peptide antibodies for mass-spectrometry-based serum biomarker detection/ quantification assays.
Monday, January 11, 2016
OriGene Technologies Announces the Acquisition of ZsBio
Acquisition establishes OriGene's leading position in the Chinese pathology testing market.
Tuesday, March 13, 2012
OriGene Releases 1500 TrueMAB™ Monoclonal Antibodies
Extensively validated monoclonal antibodies made against native protein antigens for superior IHC, IF, ELISA and flow applications.
Monday, January 24, 2011
OriGene Technologies Acquires Blue Heron Biotechnology
OriGene’s collection of human cDNA clones together with Blue Heron’s gene synthesis capacity provides a whole product solution for the life sciences community.
Tuesday, August 17, 2010
Scientific News
AACR 2016: Cancer Immunotherapy and Beyond
At this year's meeting there was a palpable buzz around subjects ranging from microbiomics to the tumor microenvironment and cancer vaccines, big data to in vitro and in vivo modeling and drug delivery (to name just a few).
How Skeletal Stem Cells Form The Blueprint Of The Face
USC researchers discover that two types of molecular signals work to control where and when stem cells turn into facial cartilage.
Intestinal Worms Boost Immune System In A Surprising Way
EPFL researchers find that intestinal worm infections cause lymph nodes to produce more immune cells as well as grow in size.
Measuring The Airborne Toxicants Urban Bicyclists Inhale
Researchers analyze breath biomarkers to measure uptake of volatile organic compounds by bicyclists.
Breast Milk Hormones Impact Bacteria In Infants’ Guts
Intestinal microbiome of children born to obese mothers significantly different from those born to mothers of healthy weight, CU Anschutz researchers find.
Newborn Screening Test Developed For Rare, Deadly Neurological Disorder
Scientists have developed a new dried blood spot screening test for Niemann-Pick type C, with goal to speed diagnosis and treatment.
'Kidney on a Chip' Facilitates Safer Drug Dosing
University of Michigan researchers have used a "kidney on a chip" device to mimic the flow of medication through human kidneys and measure its effect on kidney cells.
New Autism Blood Biomarker Identified
Researchers at UT Southwestern Medical Center have identified a blood biomarker that may aid in earlier diagnosis of children with autism spectrum disorder, or ASD.
New Method Allows First Look At Embryo Implantation
Researchers at The Rockefeller University develop a method that shows the molecular and cellular processes that occur up to day 14 after fertilization.
Shining A Light On Bladder Cancer
Researchers scrutinize patterns of mutations in bladder tumor genomes, gleaning insights into the roles of DNA repair and tobacco-related DNA damage.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!